Related Experiment Video
Updated: Jun 11, 2026
10:52
An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
Published on: April 7, 2014
Agents that bind annexin A2 suppress ocular neovascularization
Raquel Lima e Silva1, Jikui Shen, Yuan Yuan Gong
1Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA.
Journal of Cellular Physiology
|July 8, 2010
Summary
TM601, a scorpion venom-derived polypeptide, effectively suppresses ocular neovascularization (NV) by targeting annexin A2. This novel therapeutic agent shows promise in treating blinding eye diseases by reducing abnormal blood vessel growth and leakage.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Ocular neovascularization (NV) is a major cause of vision loss.
- TM601, a synthetic polypeptide from scorpion venom, targets annexin A2 and inhibits tumor angiogenesis.
- Annexin A2 is upregulated in ocular NV but not in normal ocular vessels.
Purpose of the Study:
- To investigate the efficacy of TM601 in preclinical models of ocular neovascularization (NV).
- To determine the therapeutic potential of TM601 for blinding eye diseases.
Main Methods:
- TM601 was administered via intraocular, intravenous, or periocular injections in rodent models of ocular NV.
- Effects on choroidal and retinal NV, endothelial cell apoptosis, and vascular permeability were assessed.
- Immunostaining was used to confirm TM601 binding and co-localization with annexin A2.
Main Results:
- TM601 significantly suppressed the development of choroidal and retinal NV.
- Treatment with TM601 induced apoptosis of endothelial cells and regression of established NV.
- TM601 reduced vascular endothelial growth factor-induced vascular permeability and selectively bound to NV tissues.
Conclusions:
- TM601 effectively suppresses and causes regression of ocular NV by targeting annexin A2.
- TM601 reduces ocular vascular leakage, offering potential as a novel treatment for neovascular eye diseases.
- Annexin A2 is a viable therapeutic target for treating blinding conditions like wet age-related macular degeneration and diabetic retinopathy.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...